Utilising in silico, in vitro and ‘omics New Approach Methodologies (NAMs) for..

{
  "awards": [
    {
      "aboveThreshold": true,
      "contractPeriod": {
        "endDate": "2028-05-10T23:59:59+01:00",
        "startDate": "2025-08-11T00:00:00+01:00"
      },
      "documents": [
        {
          "datePublished": "2025-07-24T16:43:17+01:00",
          "description": "Transparency notice on Find a Tender",
          "documentType": "awardNotice",
          "format": "text/html",
          "id": "042934-2025",
          "noticeType": "UK5",
          "url": "https://www.find-tender.service.gov.uk/Notice/042934-2025"
        }
      ],
      "id": "1",
      "items": [
        {
          "additionalClassifications": [
            {
              "description": "Research and development services and related consultancy services",
              "id": "73000000",
              "scheme": "CPV"
            }
          ],
          "id": "1",
          "relatedLot": "1"
        }
      ],
      "mainProcurementCategory": "services",
      "milestones": [
        {
          "dueDate": "2025-08-04T23:59:59+01:00",
          "id": "1",
          "status": "scheduled",
          "type": "futureSignatureDate"
        }
      ],
      "relatedLots": [
        "1"
      ],
      "status": "pending",
      "suppliers": [
        {
          "id": "GB-PPON-PHCQ-3464-LVTM",
          "name": "University of Birmingham"
        }
      ],
      "title": "Utilising in silico, in vitro and \u2018omics New Approach Methodologies (NAMs) for p",
      "value": {
        "amount": 488375.5,
        "amountGross": 586050.6,
        "currency": "GBP"
      }
    }
  ],
  "buyer": {
    "id": "GB-PPON-PJRM-6866-LYYX",
    "name": "Food Standards Agency"
  },
  "date": "2025-07-24T16:43:17+01:00",
  "id": "042934-2025",
  "initiationType": "tender",
  "language": "en",
  "ocid": "ocds-h6vhtk-0565d3",
  "parties": [
    {
      "address": {
        "country": "GB",
        "countryName": "United Kingdom",
        "locality": "York",
        "postalCode": "YO1 7PR",
        "region": "UKE21",
        "streetAddress": "YO1 7PR"
      },
      "contactPoint": {
        "email": "fsa.commercial@food.gov.uk",
        "name": "FSA Commercial"
      },
      "details": {
        "classifications": [
          {
            "description": "Public authority - central government",
            "id": "publicAuthorityCentralGovernment",
            "scheme": "UK_CA_TYPE"
          }
        ],
        "url": "https://www.food.gov.uk/"
      },
      "id": "GB-PPON-PJRM-6866-LYYX",
      "identifier": {
        "id": "PJRM-6866-LYYX",
        "scheme": "GB-PPON"
      },
      "name": "Food Standards Agency",
      "roles": [
        "buyer"
      ]
    },
    {
      "address": {
        "country": "GB",
        "countryName": "United Kingdom",
        "locality": "Birmingham",
        "postalCode": "B15 2TT",
        "region": "UKG31",
        "streetAddress": "Edgbaston"
      },
      "contactPoint": {
        "email": "welcome@contacts.bham.ac.uk"
      },
      "details": {
        "scale": "large",
        "url": "http://www.birmingham.ac.uk",
        "vcse": false
      },
      "id": "GB-PPON-PHCQ-3464-LVTM",
      "identifier": {
        "id": "PHCQ-3464-LVTM",
        "scheme": "GB-PPON"
      },
      "name": "University of Birmingham",
      "roles": [
        "supplier"
      ]
    }
  ],
  "tag": [
    "award",
    "contract"
  ],
  "tender": {
    "description": "A supplier needs to carry out a range of project delivery options, to deliver against stages 1, 2 and 3 as described below: Stage 1: This case study is to support the UK FSA\u2019s policy need to determine which TAs are the most potent (neuro)toxicants so as to prioritise specific substances and inform decisions on the UK\u2019s monitoring of these alkaloids in foods. An integral part of this aim is to confirm that neurotoxicity is the primary mode of action of these alkaloids. This aim will be achieved using a tiered-testing strategy of in silico, in vitro and \u2018omics NAMs. This will then be extended to other plant alkaloids such as glycoalkaloids and pyridazine alkaloids. Stage 2: To derive a HBGV for human exposure for the top priority, i.e. most potent substance within the class of TAs. This will utilise physiologically-based kinetic (PBK) modelling and quantitative in vitro to in vivo extrapolation (QIVIVE). This will then be extended to other plant alkaloids such as glycoalkaloids and pyridazine alkaloids. Stage 3: From a methodological perspective, a broader third objective of the case study is to evaluate and attempt to build confidence within the FSA in the application of a series of relevant NAMs that have been integrated in a manner to address policy needs. These NAMs are tiered and incorporate existing human in vivo data as well as new testing on human in vitro cell lines, to maximise the relevance and accuracy to human food safety.",
    "documents": [
      {
        "description": "Not published",
        "documentType": "conflictOfInterest",
        "id": "conflictOfInterest"
      }
    ],
    "id": "C367576",
    "legalBasis": {
      "id": "2023/54",
      "scheme": "UKPGA",
      "uri": "https://www.legislation.gov.uk/ukpga/2023/54/contents"
    },
    "lots": [
      {
        "id": "1",
        "status": "complete",
        "suitability": {
          "sme": true,
          "vcse": true
        }
      }
    ],
    "procurementMethod": "direct",
    "procurementMethodDetails": "Direct award",
    "procurementMethodRationale": "(a)due to a particular supplier having intellectual property rights or other exclusive rights, only that supplier can supply the goods, services or works required, and (b)there are no reasonable alternatives to those goods, services or works.",
    "procurementMethodRationaleClassifications": [
      {
        "id": "singleSuppliersIntellectualPropertyExclusiveRights"
      }
    ],
    "riskDetails": "Delays in the overall delivery of the contract. Delays in the delivery of individual Milestones and/or Deliverables. Unplanned work that must be accommodated. Selection of service providers (subcontractors) proves challenging, i.e., they do not meet our criteria for high-quality, cost-effective. Delays imposed at import and export hubs during the shipment of samples (leading to thawing and degradation of cell samples). Insufficient data quality or poor reproducibility of omics data. Proposed experimental designs induce minimal (and non-significant) toxicological responses (Tier 2) and omics responses (Tier 3). While accurate budgeting has been completed during the planning phase, deviations are noted during the course of the contract. Availability of experienced scientists with sufficient expertise to cover all aspects of the proposed contract. Training courses are delivered at the wrong level.",
    "status": "complete",
    "title": "Utilising in silico, in vitro and \u2018omics New Approach Methodologies (NAMs) for.."
  }
}